Atossa Genetics Announces $10 Million At-the-Market Common

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Atossa Genetics Announces $10 Million At-the-Market Common Stock Purchase Agreement With Aspire Capital Fund, LLC

SEATTLE, WA--(Marketwired - May 27, 2016) - Atossa Genetics, Inc. ( NASDAQ : ATOS ) today announced that it has entered into a $10 million stock purchase agreement with Aspire Capital Fund, LLC. Under terms of the agreement, after the SEC declares the registration statement related to the transaction effective, Aspire has committed to purchase up to $10 million of Atossa's common stock over 30 months, based on prevailing market prices over a period preceding each sale.

"Aspire Capital has been an important financial partner over the past three years and we look forward to continuing our work together to execute on our business objectives," stated Kyle Guse, Chief Financial Officer of Atossa Genetics. "This financial arrangement will provide us with the financial resources and flexibility so that we can raise equity based on favorable market conditions and our evolving working capital needs."

"We are very pleased to continue our financial relationship with Atossa," said Steve Martin, Principal of Aspire Capital. "We are very excited about Atossa's Phase II clinical program and are happy to be part of Atossa's progress."

Key aspects of the agreement with Aspire Capital include:

  • Atossa will control the timing and amount of any sales of common stock to Aspire Capital and will know the sales price before directing Aspire Capital to purchase shares;
  • Aspire Capital has no right to require any sales by Atossa, but is obligated to make purchases as Atossa directs, in accordance with the terms of the purchase agreement;
  • Aspire Capital has agreed to a long-only position;
  • There are no limitations on use of proceeds, financial covenants, restrictions on future financings, rights of first refusal, participation rights, penalties or liquidated damages in the purchase agreement;
  • The purchase agreement may be terminated by Atossa at any time, at its discretion, without any additional cost or penalty; and
  • Atossa has issued shares of its common stock to Aspire Capital as a commitment fee in connection with entering into the purchase agreement.
  • Atossa will use the net proceeds from the sales of common stock for general corporate purposes and working capital requirements.
  • Atossa also entered into a registration rights agreement with Aspire Capital in connection with its entry into the purchase agreement that requires the Company to file a registration statement regarding the shares sold to Aspire Capital. A more complete and detailed description of the agreement is set forth in the Company's Periodic Report on Form 8-K filed today with the U.S. Securities and Exchange Commission.

About Aspire Capital Fund, LLC

Aspire Capital is an institutional investor based in Chicago, Illinois, with a fundamental investment approach. Aspire Capital invests in a wide range of companies and industries emphasizing life sciences, energy and technology.

About Atossa Genetics

Atossa Genetics, Inc. is a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions. For more information, please visit www.atossagenetics.com .

Forward-Looking Statements

Forward-looking statements in this press release, which Atossa undertakes no obligation to update, are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with actions and inactions by the FDA, the outcome or timing of regulatory approvals needed by Atossa, lower than anticipated rate of patient enrollment, results of clinical studies, the safety and efficacy of Atossa's products and services, performance of clinical research organizations and investigators, obstacles resulting from proprietary rights held by others, such as patent rights, and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.

Atossa Genetics Company Contact: Atossa Genetics Inc. Kyle Guse CFO and General Counsel (O) 800-351-3902 kyle.guse@atossagenetics.com Investor Relations Contact: Scott Gordon CorProminence LLC (O) 516-222-2560 scottg@corprominence.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

PawnMate Boosts Inventory Efficiency for Pawnshops

Updated Category News Views 18

RFID Technology: Breathing New Life into Pawnshops Let's get things rolling with the cold, hard truth that pawnshops aren't exactly what most folks expect when it comes to cutting-edge technology. But times are a-changin', and PawnMate’s RFID Inventory Module is the latest twist in this industry storyline. It's like swapping out a rusty toolbox for a brand-new set of...

Continue Reading
ZTE Reinvents Energy for AI Data Centers

Updated Category News Views 200

The Great Race: Power and AI in Sync Here we are, neck-deep in the AI era, where the demand for raw computing power just won’t quit. With every data-hungry application and supercharged algorithm, companies are scrambling to keep up. But there’s a nasty little dragon in this fairy tale—energy efficiency. ZTE isn’t just acknowledging this beast; they’re ready to...

Continue Reading
Envision and Tsinghua Propel Climate Innovation at COP31

Updated Category News Views 95

Collaborating for a Greener Future On the bustling stage of COP31 in Antalya, Turkey, Envision Energy and Tsinghua University teamed up with the Global Alliance of Universities on Climate (GAUC) to showcase a bold agenda. Their focus transcends mere dialogue, pushing for actionable climate solutions anchored in technological innovation, academic synergy, and the dynamism...

Continue Reading
Visit W&H at the Greater New York Dental Meeting

Updated Category News Views 29

Why This Event Matters for Dental Professionals Stroll through any convention center halls and you can see the future unfolding right in front of you. The upcoming Greater New York Dental Meeting is no different, especially with W&H Group setting up shop. For any dental professionals out there, this is your chance to get your hands on some real-deal tech that might just...

Continue Reading
Teledyne LeCroy Drives AI Scale-up with New UALink

Updated Category News Views 17

Pushing the Boundaries of AI Infrastructure Teledyne LeCroy is shaking things up with their latest innovation—the Xena Z2244 Ultra Accelerator Link™ Traffic Generator, a tool that promises to turbocharge validation systems for AI and HPC scale-up infrastructure. If you're dealing with the nuts and bolts of next-gen networks, this one's worth your attention. Setting a...

Continue Reading
Biel Crystal Solidifies Position as Key iPhone UTG Supplier

Updated Category News Views 71

Biel Crystal Hones In On Foldable iPhone Tech Here's the lowdown: Apple's making waves with their first foldable phone, the iPhone Duo, and Biel Crystal? They're the rockstars cranking out that ultra-thin glass making it all possible. You might not have heard their name tossed around as much, but they're heavy hitters in the tech components scene. Biel Crystal's been...

Continue Reading
Neil deGrasse Tyson Headlines HIMSS27 with Cosmic Insights

Updated Category News Views 136

celebrated science communicator, is set to close out the HIMSS27 conference with a keynote that's bound to leave a lasting impression. It's a fitting intersection of stars and stethoscopes, as the astrophysicist brings his expansive lens to the nitty-gritty of healthcare innovation. Splicing Science with Storytelling Folks, this ain't your standard healthcare gathering....

Continue Reading
TOYO Slips on Earnings Amid Strategic Expansion

Updated Category News Views 177

TOYO's Solar Journey: Ups and Downs If there's one thing riding high on volatility these days, it's solar energy. TOYO Co., Ltd. (Nasdaq: TOYO) spilled the beans on Q3 2026, and oh boy, it's a mixed bag. Revenue Jumps, Yet Profitability Takes a Hit Let's cut to the chase: the third quarter served up a 4.8% dip in revenue year-over-year, landing at $129 million, though it...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 283

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading
Palatin's Game-Changer: MC4R Agonist Hits the Stage

Updated Category News Views 62

Breaking New Ground in Obesity Treatment Palatin Technologies is stepping into the spotlight with some heavy ammunition in the fight against obesity. The company has just unveiled impressive preclinical data about their next-generation melanocortin-4 receptor (MC4R) agonists at the ObesityWeek® 2026 conference. This isn’t just your run-of-the-mill corporate...

Continue Reading

Top 5 Most Recently Viewed Articles

Kelly Munson Takes Charge as President and CEO of Independence Health Group

Updated Category News Views 574

Kelly Munson Appointed President and CEO Independence Health Group proudly announces that Kelly A. Munson will take the role of President and Chief Executive Officer. Beginning this new chapter, she will bring with her a wealth of experience and insight derived from her tenure with AmeriHealth Caritas, which operates under the Independence Health Group umbrella....

Continue Reading
Seek AI Achieves Dual Patents, Pioneering AI Data Workflows

Updated Category News Views 201

Innovative Patents Transforming AI Data Analytics NEW YORK-- Seek AI, the agentic AI platform designed for the modern data stack, proudly announces the acquisition of two groundbreaking patents. Awarded by the United States Patent and Trademark Office (USPTO), these patents highlight Seek AI's unique approach to human-in-the-loop workflows that utilize LLM-generated...

Continue Reading
InMed Pharmaceuticals Tackles Nasdaq Compliance Challenges

Updated Category News Views 95

InMed Pharmaceuticals Faces Nasdaq Compliance Challenge InMed Pharmaceuticals Inc. (NASDAQ: INM), a biopharmaceutical firm recognized for its innovative drug development, is actively addressing a delisting notice from Nasdaq, which is due to not meeting minimum bid price regulations. The company has formally initiated an appeal to the Nasdaq Listing Qualifications Panel...

Continue Reading
Tetragon Financial Group Investor Call Highlights and Insights

Updated Category News Views 139

Join Tetragon Financial Group for a Special Investor Call Tetragon Financial Group Limited will be hosting an important investor call to provide key updates about the company. Set for Wednesday, March 5, at 15:30 GMT / 10:30 EST, this call is a significant opportunity for investors to gain insights into Tetragon's annual report and overall company performance. What to...

Continue Reading
Exploring the Future of Bleeding Disorders Treatment Market

Updated Category News Views 214

Growing Landscape of the Bleeding Disorders Treatment Market The Bleeding Disorders Treatment Market is on a significant growth trajectory as it adapts to the rising global prevalence of conditions like hemophilia and other rare coagulation disorders. This upward trend is supported by remarkable advancements in treatment options, increasing healthcare funding, and rising...

Continue Reading